<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>jmedicalcasereports</PublisherName>
<JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
<PISSN>I</PISSN>
<EISSN>S</EISSN>
<Volume-Issue>Volume 2; Issue 2, (Jul-Dec,2021)</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>Cancer Case Reports</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>-0001</Year>
<Month>11</Month>
<Day>30</Day>
</PubDate>
<ArticleType>Cancer Case Reports</ArticleType>
<ArticleTitle>Molecular Basis of Synovial Sarcoma and the Rare Case of its Localization in Palatine Tonsil: A Review of the Literature</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>1</FirstPage>
<LastPage>18</LastPage>
<AuthorList>
<Author>
<FirstName>Nikolaos Andreas</FirstName>
<LastName>Chrysanthakopoulos</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>Eleftheria</FirstName>
<LastName>Vryzaki</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Kyriakos</FirstName>
<LastName>Karkoulias</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>Synovial sarcomas (SS) are rare soft tissue malignant tumors that mainly arise from the lower extremities, especially the lower thigh-knee region. The literature has shown that this tumor may be observed in uncommon regions such as the abdominal wall and the head and neck region which are non-synovium-lined spaces. SS rarely occurs in the head and neck region, as only 3-10% of these neoplasms appear in this region. The parapharyngeal space is the most common location, whereas primary SS of the palatine tonsil is extremely rare as only a few cases of primary tonsillar SS have been described. It is considered as a high grade malignant tumor, however current investigation regarding its clinical and histopathological features revealed in all these cases a biphasic morphology. Molecular analyses detected a typical SYT gene t(X;18) (p11; q11) translocation and a representative SYT/SSX1fusion type. Immunohistochemical analysis recorded cytokeratin OSCAR, Bcl-2, EMA, vimentin, TLE1 and PGP 9.5, were diffusely positive. The aim of the current review was to present the molecular basis of SS and SS rare location in palatine tonsil.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Synovial Sarcoma,Translocation,Molecular Biology,Tonsil</Keywords>
<URLs>
<Abstract>https://www.jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=15147&title=Molecular Basis of Synovial Sarcoma and the Rare Case of its Localization in Palatine Tonsil: A Review of the Literature</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>Allander SV, Illei PB, Chen Y, Antonescu CR, Bittner M, Ladanyi Mand Meltzer PS. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002; 161: 1587-1595.
Antonescu CR, Kawai A, Leung DH, Lonardo F, Woodruff JM, Healey JH, Ladanyi M. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol 2000; 9: 1-8.
Auersperg N, Pan J, Grove BD, Peterson T, Fisher J, Maines Bandiera S, Somasiri A, Roskelley CD. E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci USA 1999; 96: 6249-6254.
BarbashinaV, Benevenia J, Aviv H, Tsai J, Patterson F, Aisner S, Cohen S, Fernandes H, Skurnick J, Hameed M. Oncoproteins and proliferation markers in synovial sarcomas: a clinico- pathologic study of 19 cases. J Cancer Res Clin Oncol 2002;128: 610-616.
Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A. The transcription factor snail is a repressor of E- cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000; 2: 84-89.
Berx G, Cleton-Jansen A-M, Nollet F, de Leeuw WJF, van de Vijver MJ, Cornelisse C, van Roy F. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995; 14: 6107-6115.
Bongiorno PF, Whyte RI, Lesser EJ, Moore JH, Orringer MB, Beer DG. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J Thorac Cardiovasc Surg 1994; 107: 590–595.
Brett D, Whitehouse S, Antonson P, Shipley J, Cooper C, Goodwin G. The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies. Hum Mol Genet 1997; 6:1559 -1564.
Brown DT. Histone H1 and the dynamic regulation of chromatin function. Biochem Biochem Cell Biol 2003; 81:221-227.
Bruijn DRH, Baats E, Zechner U, de Leeuw B, Balemans M, Weghuis Olde D, Hirning Folz U, Geurts van Kessel A. Isolation and characterization of the mouse homolog of SYT, a gene implicated in the development of human synovial sarcomas. Oncogene 1996; 13: 643-648.
Bukholm IK, Nesland JMand Borrensen-Dale AL. Re-expression of E-cadherin, alpha- catenin and beta-catenin, but not of gamma-catenin. J Pathol 2000; 190: 15-19.
Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76-83.
Chand A, Clark J, Cooper CS, Craig IW. Long-range organization of reiterated sequences, including the SSX1 cDNA at the OATL1 cluster in Xp11.23. Genomics 1995; 30: 545-552.
Chen H and Hung MC. Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene. J Biol Chem 1997; 272: 6101-6104.
Cirisano FD and Karlan BY. The role of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Invest 1996; 3: 99-105.
Clair JM, Arshi A, Abemayor E, John MS. Factors associated with survival in patients with synovial cell sarcoma of the head and neck: An analysis of 167 cases using the SEER (Surveillance, Epidemiology, and End Results) Database. JAMA Otolaryngol Head Neck Surg 2016; 142: 576-583.
Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, Gusterson BA, Cooper CS. Iden- tification of novel genes, SYT and SSX, involved in the t(X;18) (p11.2; q11.2) translocation found in human synovial sarcoma. Nat Genet 1994; 7: 502-508.
Coindre JM, Pelmus M, Hostein I, Lussan C, Bui BH, Guillou L. Should molecular testing be required for diagnosing synovial sarcoma? Cancer 2003; 98: 2700-2707.
Crew J, Clark J, Fisher C, Gill S, Grimer R, Mitchell P. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel associated box in human synovial sarcoma. EMBO J 1995; 14: 2333-2340.
Dafydd GT, Giordano TJ, Sanders D, Biermann S, Sondak VK., Trent JC, Yu D, Pollock RE, Baker L. Expression of Receptor Tyrosine Kinases Epidermal Growth Factor Receptor and HER- 2/neu in Synovial Sarcoma. Cancer 2005; 15; 103: 830-838.
de Leeuw B, Balemans M, Geurts van Kessel A. A novel Krand;uuml;ppel-associated box containing the SSX gene (SSX3) on the human X chromosome is not implicate in t(X;18) -positive sy- novial sarcomas. Cytogenet Cell Genet 1996; 73: 179-183.
de Leeuw B, Balemans M, Olde Weghuis D, Geurts van Kessel A: Identification of two alternative fusion genes, SYT-SSX1 and SYTSSX2, in t(X;18) (p11.2; q11.2)-positive synovial sarco- mas. Hum Mol Genet 1995; 4: 1097-1099.
de Leeuw B, Suijkerbuijk RF, Olde Weghuis D, Meloni AM, Stenman G, Kindblom LG, Balemans M, van den Berg E, Molenaar WM, Sandberg AA. Distinct Xp11.2 breakpoint regions in synovial sarcoma revealed by metaphase and interphase FISH: relationship to histologic subtypes. Cancer Genet Cytogenet 1994; 73: 89-94.
De Silva MV, McMahon AD, Paterson L, Reid R. Identification of poorly differentiated synovial sarcoma: a comparison of clinicopathological and cytogenetic features with those of typical synovial sarcoma. Histopathology 2003; 43: 220-230.
Dei Tos AP and Dal Cin P. The role of cytogenetics in the classification of soft tissue tu- mours. Virchows Arch A 1997; 431: 83-94.
Dei Tos AP, Dal CP, Sciot R, Furlanetto A, Rinaldo A, Dal Cin P, Da Mosto MC, Ferlito A. Synovial sarcoma of the larynx and hypopharynx. Ann Otol Rhinol Laryngol 1998; 107: 1080-1085.
Dorkin TJ, Robson CN, Neal DE. The molecular pathology of urological malignancies. J Pathol 1997; 183: 380-387.
dos Santos NR, de Bruijn DRH, Balemans M, Janssen B, Gand;auml;rtner F, Lopes JM, de Leeuw B, van Kessel AG. Nuclear localization of SYT, SSX and the synovial associated SYT-SSX fusion proteins. Hum Mol Genet 1997; 6: 1549-1558.
dos Santos NR, Torensma R, de Vries TJ, Schreurs MW, de Bruijn DR, Kater-Baats E, Ruiter DJ, Adema GJ, van Muijen GN, van Kessel AG. Heterogeneous expression of the SSX cancer/ testis antigens in human melanoma lesions and cell lines. Cancer Res 2000; 60: 1654-1662.
Eid JE, Kung AL, Scully R, Livingston DM. p300 interacts with the nuclear proto- oncoprotein SYT as part of the active control of cell adhesion. Cell 2000; 102: 839-848.
Eilber FC and Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol 2008; 97:314-320.
Endo K, Ashida K, Miyake N, Terada T. E-cadherin gene mutations in human intra- hepatic cholangiocarcinoma. J Pathol 2001; 193: 310-317.
Enzinger FM and Weiss SW. Enzinger and Weiss’s Soft Tissue Tumors, 4th ed. St Louis: Mosby; 2001.
Fisher C, de Bruij DRH, Geurts van Kessel A. World health organization classification of tumours. Synovial sarcoma. In: Fletcher CDM, Krishnan Unni K, Mertens F, editors. Tumors of soft tissue and bone. Lyon: IARCPress 2002; pp: 200-204.
Fisher C. Synovial sarcoma: ultrastructural and immunohistochemical features of epithelial differentiation in monophasic and biphasic tumors. Hum Pathol 1986; 17: 996-1002.
Fraga MF, Bardasco M, Ballester E, Ropero S, Lopez-Nieva P, Lopez-Serra L, Martand;iacute;n- Subero JI, Calasanz MJ, de Silanes IL, Setien F, Casado S, Fernandez AF, Siebert R, Stifani S, Esteller M. Epigenetic inactivation of the groucho homologue TLE1 in hematologic malignancies. Cancer Res 2008; 68: 4116-4122.
Frisman DM. Synovial Sarcoma. (Immunoquery/Immunohistochemistry Literature Database Query System web site). Available at: http://my.statdxcom/PathIQ/PanelAb.do. Accessed Dec 2012.
Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173-185.
Gaertner E, Zeren EH, Fleming MV, Colby TV, Travis WD. Biphasic synovial sarcomas arising in the pleural cavity. Am J Surg Pathol 1996; 20: 36-45.
Gambarotta G, Boccaccio C, Giordano S, Ando M, Stella MC, Comoglio PM. Ets up- regulates MET transcription. Oncogene 1996; 13: 1911-1917.
George E, Niehans GA, Swanson PE, Strickler JG, Singleton TP. Overexpression of the c-erbB-2 oncogene in sarcomas and small round-cell tumors of childhood. An Immunohistochem Invest Arch Pathol Lab Med 1992; 116: 1033-1035.
Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG. Methylation patterns of the E- cadherin 5’ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin ex- pression during metastatic progression. J Biol Chem 2000; 275: 2727-2732.
Gure AO, Tureci O, Sahin U, Tsang S, Scanlan MJ, Jager E, Knuth A, Pfreundschuh M, Old LJ, Chen YT. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer 1997; 72: 965-971.
Gusterson B, Cowley G, McIlhinney J, Ozanne B, Fisher C, Reeves B. Evidence for in- creased epidermal growth factor receptors in human sarcomas. Int J Cancer 1985; 36: 689-693.
Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in hu- man cancers. Am J Pathol 1998; 153: 333-339.
Kato H, Tjernberg A, Zhang W, Krutchinsky AN, An W, Takeuchi T, Ohtsuk Y, Sugano S, R de Bruijn D, Chait BT, Roeder RG. SYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histones. J Biol Chem 2002; 277: 5498-5505.
Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in Synovial sarcoma. N Engl J Med 1998; 338: 153-160.
Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993; 9: 317-321.
Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, Van de Vijver MJ. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999; 5: 577-586.
Khademi B, Bahranifard H, Mohammadianpanaht M, Javad Ashraf M, Azarpira N, Dehghani M. Synovial Sarcoma of the Palatine Tonsil: Report of Two Cases and Review of the Literature. Middle East Journal of Cancer 2010; 1: 141-146.
Kosemehmetoglu K, Vrana JA, Folpe AL. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol 2009; 22: 872-878.
Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JSJ, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B, Larsson O. Impact of SYT-SSX fusion type on the clinical behaviour of synovial sarcoma: a multi institutional retrospective study of 243 patients. Cancer Res 2002; 62: 135-140.
Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene 2001; 20: 5755-5762.
Ladanyi M. The emerging molecular genetics of sarcoma translocations. Diagn Mol Pathol 1995; 4: 162-173.
Laskin WB and Miettinen M. Epithelial-type and neural-type cadherin expression in malignant non carcinomatous neoplasms with epithelioid features than involve the soft tissues. Arch Pathol Lab Med 2002; 126: 425-431.
Lim FL, Soulez M, Koczan D, Thiesen HJ, Knight JC. A KRAB-related domain and a novel transcription repressor domain in proteins encoded by SSX genes that are disrupted in hu- man sarcomas. Oncogene 1998; 17: 2013-2018.
Locascio A, Vega S, de Frutos CA, Manzanares M, Nieto MA. Biological Potential of a Functional Human SNAILRetrogene. J Biol Chem 2002; 277: 38803-38809.
Machado JC, Soares P, Carneiro F, Rocha A, Beck S, Blin N, Berx G, Sobrinho-Simoes M. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 1999; 79: 459-465.
Mareel M, Behrens J, Birchmeier W, De Bruyne GK, Vleminckx K, Hoogewus A, Fiers WC and van Roy F. Down-regulation of E-cadherin expression in Madin Darby canine kidney (MDCK) cells inside tumors of nude mice. Int J Cancer 1991; 47: 922-928.
Meer S, Coleman H, Altini M. Oral synovial sarcoma: a report of 2 cases and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96: 306-315.
Meis-Kindblom JM, Stenman G, Kindblom LG. Differential diagnosis ofsmall round cell tumors. Semin Diagn Pathol 1996; 13: 213-241.
Muthamil Silambu V. A rare case of synovial sarcoma of tonsil. Department of ENT, Stanley Medical College and Hospital. University Journal of Surgery and Surgical Specialties 2020; 6: 1
Nagai M, Tanaka S, Tsuda M, EndoS, Kato H, Sonobe H, Minami A, Hiraga H, Nishihara H, Sawa H, Nagashima K. Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factorhBRM/hSNF2 alpha. Proc Natl Acad Sci USA 2001; 98: 3843-3848.
Nagayama S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, Araki N, Kusuzaki K, Nakayama T, Tsuboyama T, Nakamura T, Imamura M, Nakamura Y, Toguchida J. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 2002; 62: 5859-5866.
Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45: 457-461.
Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa K. Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 1997; 65: 195-203.
Nielsen TO, Hsu FD, O’Connell JX, Blake Gilks C, Sorensen PHB, Linn S, West RB, Long Liu C, Botstein D, Brown PO, van de Rijn M. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 1997; 2003; 163: 1449-1456.
Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O’Connell JX, Zhu S, Fero M, Sheriock G, Pollack JR, Brown PO, Botstein D, van de Rijn M. Molecular characterization of soft tissue tumours: a gene expression study. Lancet 2002; 359: 1301-1307.
Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002; 3: 155-166.
Noguchi S, Ueki T, Kawauchi S, Fukuda T, Matsuura H, Sonoda T, Tsuneyoshi M. Establishment and characterization of a new synovial sarcoma cell line, SN-SY-1: special reference to bcl-2 protein and SYT-SSX1 hybrid transcripts. Int J Cancer 1997; 72: 995-1002.
Nuciforo PG, Pellegrini C, Fasani R, Maggioni M, Coggi G, Parafioriti A, Bosari S. Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum Pathol 2003; 34: 639-645.
Oettgen P, Alani RM, Barcinski MA, Brown L, Akbarali Y, Boltax J, Kunsch C, Mun- ger K, Libermann TA. Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family. Mol Cell Biol 1997; 17: 4419-4433.
Okcu MF, Munsell M, Treuner J, Mattke A, Pappo A, Cain A, Ferrari A, Casanova M, Ozkan A, Raney B. Synovial sarcoma of childhood and adolescence: A multicenter, multivariate analysis of outcome. J Clin Oncol 2003; 21: 1602-1611.
Overduin M, Harvey TS, Bagby S, Tong KI, Yau P, Takeichi Mand Ikura M. Solution structure of the epithelial cadherin domain responsible for selective cell adhesion. Science 1995; 267: 386-389.
Ozawa M, Engel J, Kemler R. Single amino acid substitutions in one Ca2+ binding site of uvomorulin abolish the adhesive function. Cell 1990; 63: 1033-1038.
Pretto D, Barco R, Rivera J. The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. Oncogene 2006; 25: 9226-9235.
Rabbitts TH: Chromosomal translocation in human cancer. Nature 1994; 372: 143-149.
Renwick PJ, Reeves BR, Dal Cin P, Fletcher CDM, Kempski H, Sciot R, Kazmierczak B, Jani K, Sonobe H, Knight JC. Two categories of synovial sarcoma defined by diver-gent chromosome translocation breakpoints in Xp11.2, with implications for thehistologic sub-classification of synovial sarcoma. Cytogenet Cell Genet 1995; 70: 58-63.
Rodrigo I, Cato ACB, Cano A. Regulation of E-cadherin gene expression during tumor progression: the role of a new Ets-binding site and the E-pal element. Exp Cell Res 1999; 248: 358-371.
Saito T, Oda Y, Kawaguchi K, Sugimachi K, Yamamoto H, Tateishi N, Tanaka K, Matsuda S, Iwamoto Y, Ladanyi M, Tsuneyoshi M. E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma. Oncogene 2004; 23: 8629- 8638.
Saito T, Oda Y, Sakamoto A, Tamiya S, Iwamoto Y, Tsuneyoshi M. Matrix metallo- proteinase-2 expression correlates with morphological and immunohistochemical epithelial chara- cteristics in synovial sarcoma. Histopathology 2002; 40: 279-285.
Saito T, Oda Y, Sakamoto A, Tamiya S, Kinukawa N, Hayashi K, Iwamoto Y, Tsuneyoshi M. Prognostic value of the preserved expression of the E-Cadherin and catenin of the adhesion molecules and of beta-catenin mutations in synovial. J Pathol 2000; 192: 342-350.
Saito T, Oda Y, Sugimachi K, Kawaguchi K, Tamiya S, Tanaka K, Matsuda S, Sakamoto A, Iwamoto Y, Tsuneyoshi M. E-cadherin gene mutations frequently occur in synovial sar- coma as a determinant of histological features. Am J Pathol 2001; 159: 2117-2124.
Sefton M, Sanchez S, Nieto MA. Conserved and divergent roles for members of the Snail family of transcription factors in the chick and mouse embryo. Development 1998; 125: 3111-3121.
Sharma A, Susan Ko J, Billings SD. Primary cutaneous synovial sarcoma –Some- times the hoof beats are zebras. J Cutan Pathol 2021; 48: 281-284.
Shipley J, Crew J, Birdsall S, Gill S, Clark J, Fisher C, Kelsey A, Nojima T, Sonobe H, Cooper C, Gusterson B. Interphas fluorescence in situ hybridization and reverse transcription polymerase chain reaction as a diagnostic aid for synovial sarcoma. Am J Pathol 1996; 148: 559-567.
Shipley JM, Clark J, Crew AJ, Birdsall S, Rocques PJ, Gill S, Chelly J, Monaco AP, Abe S, Gusterson BA, Cooper CS. The t(X;18) (p11.2; q11.2) translocation found in human synovial sarcomas involves two distinct loci on the X chromosome. Oncogene 1994; 9: 1447-1453.
Shmookler BM, Enzinger FM, Brannon RB. Orofacial synovial sarcoma. Cancer 1982; 50: 269-276.
Smith HA and McNeel DG. The SSX Family of Cancer-Testis Antigens as Target Proteins for Tumor Therapy. Clin Dev Immunol 2010; 2010: 150591.
Soria-Cespedes D, Galvand;aacute;n-Linares AI, Oros-Ovalle C, Gaitan Gaona F, Ortiz-Hidalgo C. Primary monophasic synovial sarcoma of the tonsil: Immunohistochemical and molecular study of a case and review of the literature. Head Neck Pathol 2013; 7: 400-403.
Soulez M, Saurin AJ, Freemont PS, Knight JC. SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX colocalize with the human Polycomb group complex. Oncogene 1999; 18: 2739-2746.
Sreekantiah C, Ladanyi M, Rodriguez E, Chaganti RSK. Chromosomal aberrations in soft tissue tumors: relevance to diagnosis, classification and molecular mechanisms. Am J Pathol 1994; 144: 1121-1133.
Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993; 5: 806-811.
Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, Downs- Kelly E, Corless CL, Rubin BP, van de Rijn M, Ladanyi M, Nielsen TO. TLE1 as a diagnostic immuno- histochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 2007; 31: 240-246.
Thaete C, Brett D, Monaghan P, Whitehouse S, Rennie G, Rayner E, Cooper CS, Goodwin G. Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum Mol Genet 1999; 8: 585-591.
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
Tsuji S, Hisaoka M, Morimitsu Y, Hashimoto H, Shimajiri S, Komiya S, Ushijima M, Nakamura T. Detection of SYTSSX fusion transcript in synovial sarcoma by reverse transcriptase polymerase chain reaction using archival paraffin embedded tissues. Am J Pathol 1998; 153: 1807-1812.
Turc-Carel C, Dal Cin P, Limon J, Rao U, Li FP, Corson JM, Zimmerman R, Parry DM, Cowan JM, Sandberg AA. Involvement of chromosome X in primary cytogenetic change in hu- man neoplasia: nonrandom translocation in synovial sarcoma. Proc Natl Acad Sci USA 1987; 84: 1981-1985.
Tand;uuml;reci and;Ouml;, Sahin U, Schobert I, Koslowski M, Scmitt H, Schild HJ, Stenner F, Seitz G, Rammensee HG, Pfreundschuh M. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Research 1996; 56: 4766-4772.
Valente AL, Tull J, Zhang S. Specificity of TLE1 expression in unclassified high- grade sarcomas for the diagnosis of synovial sarcoma. Appl Immunohistochem Mol Morphol 2013; 21: 408-413.
Villarroel-Salinas J, Campos-Martinez J, Ortiz-Hidalgo C. Synovial sarcoma of the tongue confirmed by molecular detection of the SYT-SSX2 fusion gene transcript. Int J Surg Pathol 2012; 20: 386-389.
Vleminckx K, Vakaet Jr L, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66: 107-119.
Vogel U, Wehrmann M, Band;uuml;ltmann B. Synovial sarcoma of the left tonsil in a 31- year-old patient: report of a rare case. Diagnost Pathol 2007; 2: S17.
Vogel U, Wehrmann M, Eichhorn W, Band;uuml;ltmann B, Stiegler M, Wagner W. Mole- cular and clinicopathological findings in a tonsillar synovial sarcoma. A case study and review of the literature. Head Neck Pathol 2010; 4: 257-260.
Willeke F, Mechtersheimer G, Schwarzbach M, Weitz J, Zimmer D, Lehnert T, Herfarth C,von Knebel Doeberitz M, Ridder R. Detection of SYTSSX1/2 fusion transcripts by reverse transcriptase-Polymerase chain reaction (RT-PCR) is a valuable diagnostic tool in Synovial sarcoma. Eur J Cancer 1998; 34: 2087-2093.
Yakushiji T, Yonemura K, Tsuruta J, Nishida K, Kato T, Takagi K. Capacity for epithelial differentiation in synovial sarcoma: analysis of a new human cell line. J Clin Pathol 2000; 53: 525-531.
Yarden Y. The EGFR family and its ligands in human cancer. Signaling mecha- nisms and therapeutic opportunities. Eur J Cancer 2001; 37: S3-S8.
Yoo J, Park S, Kang CS, Kang SJ, Kim BK. Expression of E-cadherin and p53 proteins in human soft tissue sarcomas. Arch Pathol Lab Med 2002; 126: 33-38.</References>
</References>
</Journal>
</Article>
</ArticleSet>